First mRNA Flu Shot Hits Pharmacies But Only For Adults 50 Plus

Pharmacies are reporting a wave of questions about the new mRNA flu vaccine. Many patients feel unsure about who qualifies and how this shot differs from the usual options. The vaccine, called mFlusiva, comes from Moderna and uses the same messenger RNA technology found in COVID shots. It marks the first time this platform has been approved for influenza in the United States.

The Food and Drug Administration gave the green light in August but with a clear age restriction. Only people who have reached their fiftieth birthday can receive it. Adults between fifty and sixty-four received standard approval. Those sixty-five and older got accelerated approval, which means Moderna must run another study in that group. Anyone under fifty will need to stick with traditional flu vaccines this season.

Traditional flu shots typically use inactivated virus particles, often grown in chicken eggs, to train the immune system. The mRNA version works differently. It delivers a tiny piece of genetic code that tells cells to make a harmless viral protein. The immune system learns to recognize that protein and builds defenses. The genetic material breaks down quickly and does not stay in the body. Protection takes about two weeks to develop after the injection.

A large study published in May showed the new vaccine was roughly twenty-seven percent more effective than a standard dose shot. However, the trial compared it against a regular vaccine in older adults, even though health officials usually recommend a high-dose version for that age group. That detail sparked debate during the review process. The FDA advisory panel eventually voted unanimously to support approval.

One common point of confusion is whether this shot also guards against COVID. It does not. It targets only influenza strains — two type A and one type B — just like other seasonal flu vaccines this year. A key advantage is speed. Traditional production takes about six months. Moderna says its method can be ready in two to three months. That extra time lets scientists wait longer before picking which strains to target, potentially improving the match with circulating viruses. The Centers for Disease Control and Prevention suggests getting vaccinated by the end of October.